Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Pharma
Gilead's PrEP shows early promise in once-yearly dosing
Once-yearly lenacapavir achieved blood concentrations that exceeded those associated with the strong efficacy that its twice-yearly version showed.
Angus Liu
Mar 11, 2025 2:30pm
Incyte posts mixed Opzelura results in prurigo nodularis
Mar 10, 2025 11:23am
AstraZeneca says Imfinzi keeps stomach cancer from coming back
Mar 7, 2025 9:48am
AZ, Daiichi's Enhertu delivers survival win in stomach cancer
Mar 3, 2025 3:43pm
Amgen, AZ Tezspire sinusitis data invite 'best-in-disease' talk
Mar 3, 2025 11:52am
Exelixis shifts focus as triplet misses OS mark in kidney cancer
Feb 18, 2025 1:30pm
